Plasma DOPA and growth hormone in parkinsonism

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Neurology

• Publication date

  1979-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.29.2.194PMID 571063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using a single column of strongly acidic cation exchange resin.

  2009cited by this paper
• Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.

  1977cited by this paper
• Somatostatinoma.

  1977cited by this paper
• The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.

  1977cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Effects of somatostatin in parkinsonism, growth hormone, and dopa metabolism.

  1977cited by this paper
• Alkaloid products in the metabolism of alcohol and biogenic amines.

  1976cited by this paper
• Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

  1976cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Patterns of clinical response and plasma dopa levels in Parkinson's disease

  1975cited by this paper
• On‐off response

  1975cited by this paper
• A sensitive, rapid, and economic radioimmunoassay of human growth hormone using ethanol-ammonium acetate.

  1975cited by this paper
• “On‐off” phenomenon with levodopa therapy in parkinsonism

  1974cited by this paper
• Short- and long-term approaches to the "on-off" phenomenon.

  1974cited by this paper
• Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's disease

  1974cited by this paper
• Sulphate Conjugation and L-Dopa Treatment of Parkinsonian Patients

  1973cited by this paper
• Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.

  1973cited by this paper
• Plasma concentration of levodopa in patients with Parkinson's disease.

  1973cited by this paper
• DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.

  1973cited by this paper
• Value of plasma-dopa determinations in the management of Parkinson's disease.

  1973cited by this paper
• Treatment of Parkinsonism : the role of dopa decarboxylase inhibitors

  1973cited by this paper
• SIDE-EFFECTS OF LEVODOPA

  1972cited by this paper
• Catecholamine metabolism during oral administration of levodopa.

  1972cited by this paper
• Absorption and metabolism of levodopa.

  1971cited by this paper
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper
• Levodopa in Parkinsonism

  1971cited by this paper
• Similarities between neurologic effects of L-dopa and of apomorphine.

  1970cited by this paper
• L-dopa treatment failure: explanation and correction.

  1970cited by this paper

• Study on the Striatal Doparnine Availability in Parkinson ' s Disease

  2007cites this paper
• Correlation between viral dna load and serum anti p19 antibody concentrationtn symptomless human T‐lymphotropic virus type‐I (HTLV‐I)‐infected individuals

  2006cites this paper
• Running the gamut of retroviral variation.

  1996cites this paper
• Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.

  1989cites this paper
• The promise and limitations of controlled-release oral levodopa administration.

  1989cites this paper
• Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites.

  1989cites this paper
• Pathogenetic studies of motor fluctuations in Parkinson's disease.

  1988cites this paper
• Central mechanisms and levodopa response fluctuations in Parkinson's disease.

  1988cites this paper
• Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients

  1988cites this paper
• Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

  1987cites this paper
• Clinical Pharmacokinetics of Anti-Parkinsonian Drugs

  1987cites this paper
• Controlled‐release levodopa/carbidopa.

  1987cites this paper
• Controlled‐release levodopa/carbidopa.: II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease

  1987cites this paper
• Controlled‐release levodopa/carbidopa

  1987cites this paper
• Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

  1987cites this paper
• On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

  1984cites this paper
• Study on the striatal dopamine availability in Parkinson's disease.

  1984cites this paper
• Pharmacokinetics of levodopa.

  1984cites this paper
• Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.

  1982cites this paper
• Fluctuations of disability in Parkinson's disease – clinical aspects

  1981cites this paper
• Author index to volume XXIX

  1979cites this paper
• Administration of human somatotropin in levodopa-treated patients with Parkinsonism.

  1979cites this paper